Barely Significant
← all phrases

“a numerical trend”

1,013 sentences · 1,013 papers · 1,817 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

The two-way interaction of MC and S-R compatibility was non-significant too, F (1, 39) = 3.128, p = .085, η 2 p = .074, with only a numerical trend for a larger effect of S-R compatibility in the modality-incompatible condition (94 ms) than in the modality-compatible condition (73 ms). 2 Bayesian analysis The follow-up Bayesian repeated-measures ANOVA yielded, for RT, moderate evidence for H 0 concerning both the interaction of MC and S-R compatibility (BF 10 = 0.23) as well as concerning the three-way interaction of MC, S-R compatibility, and switching (BF 10 = 0.25).
21 However, the REALISTIC study showed similar improvements in DAS28(CRP) and ACR20, 50 and 70 responses when patients were stratified by prior anti-TNF use; although a numerical trend for higher response rates was observed in anti-TNF-naïve patients. 22 Similarly, the results from the South Swedish Arthritis Treatment Group Register showed that first-time anti-TNF switchers had similar response rates to anti-TNF-naïve patients. 23 Patient-reported outcomes showed CZP treatment improved symptoms such as fatigue and arthritis associated pain through Week 104.
The confidence intervals of the hazard ratios in each group exceeded 1, and all p -values were greater than 0.05, indicating no significant differences in survival rates between the subgroups (Table 2 ).Some subgroups, particularly those with clinical stage I patients (HR = 2.15), demonstrated a numerical trend; however, none achieved statistical significance.
In the severe hypoalbuminemia cohort (baseline serum albumin ≤2.8 g/dL), a numerical trend toward improved survival was observed with albumin supplementation; however, this effect did not attain statistical significance(HR 0.80, 95%CI 0.41–1.58) ( Figure 3 ). 5 Discussion In the propensity score-matched cohort of SIMI patients with comparable baseline albumin levels (mean 2.8 g/dL in both groups; p = 0.142), albumin administration demonstrated no mortality benefit across all evaluated endpoints: 28-day, 60-day, and 90-day mortality, as well as in-hospital mortality.
Shorter dosing interval regimens of denosumab showed a numerical trend for better inhibition of bone destruction, while significant differences among denosumab groups were not confirmed.